Showing 2709 results
-
Biography /
-
-
Press release /Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolioC3 glomerulopathy (C3G)…
-
-
-
-
Event /Novartis will announce the company’s fourth quarter and 2025 full year financial results.
-
-
Event /Novartis announced the company’s financial results for the third quarter of 2022.
-
Event /Novartis announces the company’s financial results for the third quarter of 2025.